These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 14666606)

  • 1. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
    Trulson I; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
    Muley T; Herth FJ; Heussel CP; Kriegsmann M; Thomas M; Meister M; Schneider MA; Wehnl B; Mang A; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S219-S232. PubMed ID: 37840518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
    Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of CYFRA 21-1 and CEA as prognostic and predictive markers in locally advanced and metastatic gastric carcinoma.
    Gopal V; Nisha Y; Ganesan P; Kayal S; Bobby Z; Adithan S; Penumadu P; Ramakrishnalay VP; Bandlamudi BP; Bahttacharjee A; Dahagama S; Dubashi B
    J Cancer Res Ther; 2024 Jan; ():. PubMed ID: 38261458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-analytical stability of the CEA, CYFRA 21.1, NSE, CA125 and HE4 tumor markers.
    Canki E; Schuurbiers MM; Linders TC; Korse CM; van den Heuvel MM; van Herwaarden AE; van Rossum HH
    Tumour Biol; 2024; 46(s1):S15-S25. PubMed ID: 37302060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.
    Muley T; Schneider MA; Meister M; Thomas M; Heußel CP; Kriegsmann M; Holdenrieder S; Wehnl B; Rolny V; Mang A; Gerber R; Herth F
    Tumour Biol; 2024; 46(s1):S163-S175. PubMed ID: 37840516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trajectory patterns and cumulative burden of CEA during follow-up with non-small cell lung cancer outcomes: A retrospective longitudinal cohort study.
    Li C; Liu L; You R; Li Y; Pu H; Lei M; Fan B; Lv J; Liu M; Yan G; Li Z; You D; Zhang T
    Br J Cancer; 2024 May; 130(11):1803-1808. PubMed ID: 38594371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of preoperative exercise tolerance in patients with early-stage lung cancer.
    Fukui M; Matsunaga T; Hattori A; Takamochi K; Tomita H; Nojiri S; Suzuki K
    J Thorac Cardiovasc Surg; 2024 Jan; ():. PubMed ID: 38218531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
    Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
    Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
    Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y
    Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of Cyfra 21-1 estimation for lung cancer patients.
    Szturmowicz M; Sakowicz A; Rudzinski P; Zych J; Wiatr E; Zaleska J; Rowinska-Zakrzewska E
    Int J Biol Markers; 1996; 11(3):172-7. PubMed ID: 8915713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of radiomic features, clinic characteristics, and serum tumor biomarkers to predict the possibility of the micropapillary/solid component of lung adenocarcinoma.
    Xing X; Li L; Sun M; Zhu X; Feng Y
    Ther Adv Respir Dis; 2024; 18():17534666241249168. PubMed ID: 38757628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia.
    Hanafi AR; Jayusman AM; Sutandyo N; Kurniawati S; Setiawan L; Diandra A; Hidayat K
    Cureus; 2022 Sep; 14(9):e29386. PubMed ID: 36304376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
    Dall'Olio FG; Abbati F; Facchinetti F; Massucci M; Melotti B; Squadrilli A; Buti S; Formica F; Tiseo M; Ardizzoni A
    Ther Adv Med Oncol; 2020; 12():1758835920952994. PubMed ID: 33193825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis.
    Yu Z; Zhang G; Yang M; Zhang S; Zhao B; Shen G; Chai Y
    Oncotarget; 2017 Jan; 8(3):4043-4050. PubMed ID: 28008142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic correlation of serum carcinoembryonic antigen and cytokeratin 19 fragment in resected nonsmall cell lung cancer.
    Lee S; Lee CY; Kim DJ; Hong DJ; Lee JG; Chung KY
    Korean J Thorac Cardiovasc Surg; 2013 Jun; 46(3):192-6. PubMed ID: 23772406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.
    Edelman MJ; Hodgson L; Rosenblatt PY; Christenson RH; Vokes EE; Wang X; Kratzke R
    J Thorac Oncol; 2012 Apr; 7(4):649-54. PubMed ID: 22425913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making.
    Scott A; Salgia R
    Biomark Med; 2008 Dec; 2(6):577-586. PubMed ID: 19802373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
    Muley T; Dienemann H; Ebert W
    Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.